Effect of omalizumab as add-on therapy to quality of life questionnaire for korean asthmatics (Kaqlq) in korean patients with severe persistent allergic asthma

Jae Woo Jung, Hae Sim Park, Choon Sik Park, Sang Heon Cho, Inseon S. Choi, Hee Bom Moon, Soon Seog Kwon, Ho Joo Yoon, Jung Won Park, Jong Myung Lee, Dong Chull Choi, Byoung Whui Choi

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)

Abstract

Background/Aims: Omalizumab is the first biologic known to be effective in patients with severe allergic asthma. Methods: This study was conducted as a multicenter, single-group, open trial to evaluate the improvement in the quality of life with the additional administration of omalizumab for 24 weeks in Korean patients with severe persistent allergic asth-ma. Results: Of the 44 patients, 31.8% were men and the mean age was 49.8 ± 11.8 years. A score improvement of 0.5 points or more in the Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) was noted in 50.0% (22/44) of the patinets. In the improved group, the baseline total immunoglobulin E (IgE) level and the amount of omalizumab used were higher, and the day and night asthma symptoms were more severe, compared to those in the non-improved group. According to the Global Evaluation of Treatment Effectiveness, favorable outcomes were found in 78.6% of patients. The Korean asthma control test (p < 0.005) and forced expira-tory volume in 1 second % predicted (FEV1%; p < 0.01) improved significantly in patients who received omalizumab treatment, compared to that at week 0, and the total dose of rescue systemic corticosteroids significantly decreased (p < 0.05). The improved group on KAQLQ showed a significant improvement in FEV1% (p < 0.001). Conclusions: Omalizumab can be considered a biological treatment for Korean patients with severe allergic asthma. It is recommended to consider omalizumab as add-on therapy in patients with high baseline total IgE levels and severe asthma symptoms.

Original languageEnglish
Pages (from-to)1001-1013
Number of pages13
JournalKorean Journal of Internal Medicine
Volume36
Issue number4
DOIs
Publication statusPublished - 2021 Jul

Bibliographical note

Publisher Copyright:
© 2021 The Korean Association of Internal Medicine.

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Fingerprint

Dive into the research topics of 'Effect of omalizumab as add-on therapy to quality of life questionnaire for korean asthmatics (Kaqlq) in korean patients with severe persistent allergic asthma'. Together they form a unique fingerprint.

Cite this